Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:IBRX NASDAQ:IDYA NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$70.15+1.3%$70.40$31.99▼$80.20$8.62B0.421.69 million shs1.29 million shsIBRXImmunityBio$7.10-1.4%$7.55$1.95▼$12.43$7.54B0.0313.86 million shs8.79 million shsIDYAIDEAYA Biosciences$28.98+0.5%$29.89$20.50▼$39.28$2.53B-0.051.06 million shs617,100 shsKRYSKrystal Biotech$317.97-1.1%$288.44$127.99▼$331.49$9.48B0.53236,000 shs291,320 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+3.28%-4.18%-7.41%+15.33%+109.21%IBRXImmunityBio+3.15%-1.23%-11.33%-14.18%+122.22%IDYAIDEAYA Biosciences+4.49%-1.30%+2.56%-12.84%+31.57%KRYSKrystal Biotech+2.93%+4.47%+3.62%+30.05%+130.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$70.15+1.3%$70.40$31.99▼$80.20$8.62B0.421.69 million shs1.29 million shsIBRXImmunityBio$7.10-1.4%$7.55$1.95▼$12.43$7.54B0.0313.86 million shs8.79 million shsIDYAIDEAYA Biosciences$28.98+0.5%$29.89$20.50▼$39.28$2.53B-0.051.06 million shs617,100 shsKRYSKrystal Biotech$317.97-1.1%$288.44$127.99▼$331.49$9.48B0.53236,000 shs291,320 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+3.28%-4.18%-7.41%+15.33%+109.21%IBRXImmunityBio+3.15%-1.23%-11.33%-14.18%+122.22%IDYAIDEAYA Biosciences+4.49%-1.30%+2.56%-12.84%+31.57%KRYSKrystal Biotech+2.93%+4.47%+3.62%+30.05%+130.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.86Moderate Buy$99.3041.55% UpsideIBRXImmunityBio 2.71Moderate Buy$14.20100.00% UpsideIDYAIDEAYA Biosciences 2.82Moderate Buy$50.6974.91% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.111.93% UpsideCurrent Analyst Ratings BreakdownLatest IDYA, CYTK, KRYS, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026IDYAIDEAYA Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$58.006/2/2026IDYAIDEAYA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/2/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.006/2/2026IDYAIDEAYA Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$58.006/1/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/22/2026IDYAIDEAYA Biosciences Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/21/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/20/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$99.005/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy5/18/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$88.04M99.15N/AN/A($5.39) per share-13.01IBRXImmunityBio$113.29M65.64N/AN/A($0.51) per share-13.92IDYAIDEAYA Biosciences$218.71M11.64N/AN/A$11.67 per share2.48KRYSKrystal Biotech$389.13M24.09$7.21 per share44.11$42.06 per share7.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)IBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)IDYAIDEAYA Biosciences-$113.70M-$1.60N/AN/AN/AN/A-14.24%-13.09%8/4/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4842.5130.23N/A53.92%19.25%17.62%8/3/2026 (Estimated)Latest IDYA, CYTK, KRYS, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/5/2026Q1 2026IDYAIDEAYA Biosciences-$1.07-$1.11-$0.04-$1.11$5.04 million$6.56 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A4.214.21IBRXImmunityBioN/A6.676.66IDYAIDEAYA BiosciencesN/A10.7410.74KRYSKrystal BiotechN/A9.469.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AIBRXImmunityBio8.58%IDYAIDEAYA Biosciences98.29%KRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.60%IBRXImmunityBio69.48%IDYAIDEAYA Biosciences4.70%KRYSKrystal Biotech13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250124.43 million121.20 millionOptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableIDYAIDEAYA Biosciences8087.86 million83.73 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableIDYA, CYTK, KRYS, and IBRX HeadlinesRecent News About These CompaniesKrystal Biotech (NASDAQ:KRYS) Sets New 52-Week High - What's Next?June 12 at 4:16 AM | americanbankingnews.comErste Asset Management GmbH Sells 12,500 Shares of Krystal Biotech, Inc. $KRYSJune 11 at 4:08 AM | marketbeat.com11,682 Shares in Krystal Biotech, Inc. $KRYS Bought by Natixis Advisors LLCJune 10 at 5:19 AM | marketbeat.comKrystal Biotech, Inc. $KRYS Shares Acquired by Fiera Capital CorpJune 10 at 4:08 AM | marketbeat.comTD Asset Management Inc Has $13.35 Million Holdings in Krystal Biotech, Inc. $KRYSJune 9 at 5:08 AM | marketbeat.comBNP Paribas Financial Markets Has $13.29 Million Stock Holdings in Krystal Biotech, Inc. $KRYSJune 8, 2026 | marketbeat.comIs Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?June 7, 2026 | insidermonkey.comNorges Bank Acquires New Shares in Krystal Biotech, Inc. $KRYSJune 7, 2026 | marketbeat.comSuma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) StockJune 7, 2026 | americanbankingnews.comInsider Selling: Krystal Biotech (NASDAQ:KRYS) Insider Sells 25,000 Shares of StockJune 6, 2026 | insidertrades.comIs the Options Market Predicting a Spike in Krystal Biotech Stock?June 5, 2026 | zacks.comKrystal Biotech Stock Soars 16% in Three Months: Here's WhyJune 4, 2026 | zacks.comWhy Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?June 3, 2026 | zacks.comH.C. Wainwright Sticks to Their Buy Rating for Krystal Biotech (KRYS)June 2, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)June 2, 2026 | theglobeandmail.comFisher Asset Management LLC Invests $933,000 in Krystal Biotech, Inc. $KRYSMay 31, 2026 | marketbeat.comKrystal Biotech (NASDAQ:KRYS) EVP John Charles Thomas Sells 642 SharesMay 28, 2026 | insidertrades.comHere's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum StockMay 26, 2026 | zacks.comEpidermolysis Bullosa: New Therapies Target Genetics, Wound HealingMay 25, 2026 | medscape.comMWilliam Blair Investment Management LLC Has $92.78 Million Stock Holdings in Krystal Biotech, Inc. $KRYSMay 24, 2026 | marketbeat.comCorbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference CallMay 21, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIDYA, CYTK, KRYS, and IBRX Company DescriptionsCytokinetics NASDAQ:CYTK$70.15 +0.88 (+1.27%) Closing price 04:00 PM EasternExtended Trading$69.85 -0.30 (-0.43%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.ImmunityBio NASDAQ:IBRX$7.10 -0.10 (-1.39%) Closing price 04:00 PM EasternExtended Trading$7.10 +0.01 (+0.07%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.IDEAYA Biosciences NASDAQ:IDYA$28.98 +0.14 (+0.49%) Closing price 04:00 PM EasternExtended Trading$29.38 +0.40 (+1.38%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$317.97 -3.58 (-1.11%) Closing price 04:00 PM EasternExtended Trading$318.50 +0.53 (+0.17%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
